Algal Protein MarketSize, Share & Industry Analysis, 2026-2034By SourceBy Product FormBy ApplicationBy Cultivation MethodBy Distribution Channel

Algal protein refers to protein derived from cultivated microalgae and macroalgae species, primarily spirulina and chlorella, marketed as protein-dense powders, tablets, capsules and liquid extracts. It is used by dietary supplement and nutraceutical brands, food and beverage manufacturers formulating plant-based and functional products, animal feed and aquafeed producers, and cosmetics and personal care formulators. Buyers range from bulk ingredient purchasers integrating algae protein into branded products to specialty retailers selling algae-based supplements directly to consumers.

The global algal protein market stood at USD 1015 million in 2025. A forecast-period rate of 8.9% takes it to USD 2185 million by 2034, and the study reports every year in between, passing USD 620 million in 2020, USD 935 million in 2024, USD 1105 million in 2026 and USD 1565 million in 2030.

Composition changes more than the total does. Chlorella, at 10.26%, outgrows Spirulina at 7.84%, and its share moves from 34% to 38%. Spirulina stays the largest line throughout, at USD 487.2 million in 2025 and USD 961.4 million in 2034. The lines gaining share are Chlorella. Spirulina and Other Algae lose share without losing revenue.

The product form split puts Powder first, at USD 588.7 million and 58% of revenue in 2025, rising to USD 1201.75 million and 55% in 2034. Liquid Extracts grows faster at 9.87% against 8.25%, moving from 12% of revenue to 13% by 2034. It cuts the same total as the source axis from a different commercial angle, so revenue does not add across the two.

Asia Pacific is the largest region at 34% of 2025 revenue, worth USD 345.1 million and reaching USD 808.45 million by 2034. North America follows at 28%, moving from USD 284.2 million to USD 546.25 million, and Middle East and Africa is the smallest at 6%. Asia Pacific, Latin America and Middle East and Africa gain share across the period, so growth is not distributed evenly between regions.

Behind these figures sit five regions, three source lines and five segmentation axes, each reported for every year from 2020 to 2034. The headline 2025 value is triangulated from published sources and category proxies, with no independently sourced count behind it, and the same applies to the segment, regional and country breakdowns drawn from it.

• The global algal protein market moves from USD 620 million in 2020 to USD 1015 million in 2025 and USD 2185 million by 2034, the forecast period compounding at 8.9% a year.
• Spirulina is the largest source line at USD 487.2 million in 2025, a 48% share, reaching USD 961.4 million and 44% of revenue by 2034.
• At 10.26%, Chlorella grows faster than any other source line, moving from USD 345.1 million and 34% of revenue in 2025 to USD 830.3 million and 38% in 2034.
• Scenario range for 2034 runs from USD 1922.8 million in the bear case to USD 2447.2 million in the bull case, against a base-case USD 2185 million, the spread a plan built on this forecast has to absorb.
• The largest region is Asia Pacific, generating USD 345.1 million in 2025 (34% of the global total) and USD 808.45 million by 2034, ahead of North America at 28%.
• Within Asia Pacific, China is the worked country example, at USD 144.9 million in 2025; 42% of regional revenue in the base year, and USD 339.6 million by 2034.
• Fifteen years are reported, 2020 to 2034 with 2025 as the base: revenue, share and growth rate per line, per axis and per region, not as a single blended series.

Three movements define the forecast period in the global algal protein market: how the source mix changes, where regional weight shifts, and the rate at which the total compounds.

Not one of them points downward. Growth is everywhere in absolute terms, and the interest is entirely in where it lands.

Composition shifts on the source axis. Between 2026 and 2034, 10.26% growth in Chlorella against 7.84% in Spirulina pulls the source mix apart. Shares follow: 34% to 38% for Chlorella, 48% to 44% for Spirulina. The revenue figures behind that are USD 345.1 million to USD 830.3 million and USD 487.2 million to USD 961.4 million. Both expand; where a supplier sits on the axis still decides whether it tracks the market.

The regional balance moves. Asia Pacific moves from 34% of revenue in 2025 to 37% in 2034, worth USD 345.1 million rising to USD 808.45 million; Latin America moves from 8% of revenue in 2025 to 9% in 2034, worth USD 81.2 million rising to USD 196.65 million; Middle East and Africa moves from 6% of revenue in 2025 to 7% in 2034, worth USD 60.9 million rising to USD 152.95 million. The remaining regions grow in absolute terms while giving up share: North America at 28% moving to 25%, Europe at 24% moving to 22%. Growth is therefore not something a participant inherits from the market; it depends on which regions its revenue is weighted toward.

Fifteen years without a discontinuity. The market moves through USD 620 million in 2020, USD 935 million in 2024, USD 1015 million in 2025, USD 1105 million in 2026, USD 1565 million in 2030 and USD 2185 million in 2034. No year breaks the trajectory, and the 8.9% forecast rate compares with 10.36% recorded over 2020-2025, a continuation, not an inflection. For a participant that makes planning a question of capturing a share of steady expansion instead of timing a discontinuity, and it is why the source and regional mixes matter more to a forecast than the headline rate does.

Chlorella adds the most incremental growth

Growth in the global algal protein market comes from three measurable sources over 2026-2034: the market's own compounding at 8.9%, the share gained by faster-growing source lines, and expansion in the regions taking a larger part of global revenue.

What holds the forecast back

Where the forecast could be beaten

Revenue is concentrated in Spirulina

In North America, 28% of global revenue puts 2025 at USD 284.2 million with USD 546.25 million projected for 2034. By revenue it sits second across the study, and the ranking does not change between 2025 and 2034.

Its share moves to 25% by 2034, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.

Spirulina leads here as it does globally, at 48% of 2025 revenue, and Chlorella again grows fastest at 10.26%. Revenue for North America is broken out by every segmentation axis and by country in the full report.

The United States is the largest market within North America, generating USD 241.6 million in 2025 and projected to reach USD 464.3 million by 2034. Because it is 85% of the region in the base year, North America's totals move with this one country instead of a spread of them. Regional revenue of USD 284.2 million in 2025 and USD 546.25 million in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

The source pattern in the United States is the global one: 48% of 2025 revenue in Spirulina, 44% by 2034, against 10.26% growth in Chlorella taking it from 34% to 38%. Because the country carries 85% of North America, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. The full report reports the United States by source separately.

Algal protein intended for human consumption falls under the Food and Drug Administration, which treats most microalgae-derived proteins as conventional food ingredients or as substances subject to Generally Recognized as Safe review depending on the specific algal species and production method. A supplier bringing a new algal strain or novel extraction process to market typically needs to establish GRAS status, either through self-affirmation supported by safety data or through formal FDA notification. Labelling must comply with FDA and USDA guidance on nutrient content claims, allergen disclosure, and ingredient naming, and manufacturing facilities are expected to operate under current Good Manufacturing Practice. Where the product is marketed as a dietary supplement rather than a food ingredient, it instead falls under the Dietary Supplement Health and Education Act framework, which shifts responsibility for safety substantiation onto the manufacturer rather than requiring premarket approval.

Supplier positions in the United States sit on the source axis: the country buys the same lines the global market does, in the same order. The commercially relevant division is 48% of 2025 revenue in Spirulina, where the volume is, against 10.26% growth in Chlorella, where share moves. Country-level positioning and shares for each of these companies are part of the full report, not of this summary.

Canada is sized at USD 42.6 million in 2025, rising to USD 81.9 million by 2034; 4.2% of global revenue and 15% of North America. It is reported separately from the United States across every segmentation axis in the full report.

24% of the global algal protein market sits in Europe in 2025, worth USD 243.6 million on the way to USD 480.7 million by 2034. That makes it the third-largest region covered, in 2025 and again in 2034.

Share settles at 22% in 2034, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.

Within the region the source split tracks the global one; 48% of 2025 revenue in Spirulina, fastest growth of 10.26% in Chlorella. The full report breaks Europe out along every axis and by country.

USD 82.8 million of Europe's 2025 revenue is generated in Germany, the region's largest market, reaching USD 163.4 million by 2034. 34% of the region in the base year makes it the largest market here without making it the region. Set against USD 243.6 million and USD 480.7 million for the region, it is why this market, and not a smaller one, is the one reported in full.

Germany buys along the same lines as the market globally; Spirulina first at 48% of 2025 revenue and 44% in 2034, Chlorella fastest at 10.26% on a share moving from 34% to 38%. Its 34% weight in Europe means those movements carry straight into the regional totals. Germany carries its own source breakdown in the full report.

As an EU member state, Germany applies the Novel Food Regulation to algal protein ingredients that lack a documented history of consumption within the Union before the regulation's cutoff date, meaning most microalgae species used for protein extraction require authorisation before sale. A supplier must secure inclusion on the EU list of authorised novel foods, a process that involves a safety dossier reviewed by the European Food Safety Authority, or rely on an existing authorisation already granted to that species and production method. Once authorised, the product must meet the labelling requirements of the Food Information to Consumers Regulation, including clear ingredient declaration and any conditions attached to the novel food approval itself. German authorities, coordinated through the Federal Office of Consumer Protection and Food Safety, enforce these requirements at the national level alongside standard EU food safety and traceability obligations.

Competition in Germany is decided on the source axis rather than on geography, since suppliers here sell into the same source lines reported globally. The commercially relevant division is 48% of 2025 revenue in Spirulina, where the volume is, against 10.26% growth in Chlorella, where share moves. The commercial size of that position is USD 243.6 million in 2025 and USD 480.7 million by 2034, 24% of the global total in the base year.

Within Europe, France accounts for 28% of regional revenue and 6.72% of the global total, worth USD 68.2 million in 2025 and USD 134.6 million by 2034.

5.76% of global revenue is generated in the United Kingdom; USD 58.5 million in 2025, reaching USD 115.4 million in 2034, and 24% of Europe.

In Asia Pacific, 34% of global revenue puts 2025 at USD 345.1 million on the way to USD 808.45 million by 2034. That makes it the first-largest region covered, in 2025 and again in 2034.

By 2034 the share has moved up to 37%, at a pace above the 8.9% global rate, so this region warrants separate treatment and should not be scaled off the total.

The source mix reported at global level applies here, with Spirulina the largest line at 48% of 2025 revenue and Chlorella the fastest-growing at 10.26%. Per-axis and per-country detail for Asia Pacific sits in the full report.

China is the largest market within Asia Pacific, generating USD 144.9 million in 2025 and projected to reach USD 339.6 million by 2034. 42% of the region in the base year makes it the largest market here without making it the region. Regional revenue of USD 345.1 million in 2025 and USD 808.45 million in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Demand in China follows the source mix reported at global level: Spirulina is the largest line at 48% of 2025 revenue, moving to 44% by 2034, while Chlorella grows fastest at 10.26% and takes its share from 34% to 38%. Its 42% weight in Asia Pacific means those movements carry straight into the regional totals. Revenue by source for China is reported separately in the full report.

Algal protein products sold in China fall under the food safety framework administered by the State Administration for Market Regulation, with the National Health Commission responsible for determining whether a given algal source is approved for use as a food ingredient or new food raw material. Species without an established history of use in Chinese food production generally require listing as a new food raw material before commercial sale, a process that involves submission of safety and nutritional data to the health authority. Labelling must conform to the national food safety standard governing prepackaged food labels, covering ingredient listing, nutrition information, and any functional claims, which are separately restricted under rules for health food registration. Importers of algal protein ingredients must also satisfy customs and inspection requirements administered through the national market regulator before goods clear entry into domestic distribution.

Competition in China is decided on the source axis rather than on geography, since suppliers here sell into the same source lines reported globally. Volume sits in Spirulina at 48% of 2025 revenue; movement sits in Chlorella at 10.26% growth. The commercial size of that position is USD 345.1 million in 2025, moving to USD 808.45 million by 2034 across the forecast period.

6.12% of global revenue is generated in India; USD 62.1 million in 2025, reaching USD 145.5 million in 2034, and 18% of Asia Pacific.

Japan is sized at USD 55.2 million in 2025, rising to USD 129.4 million by 2034; 5.44% of global revenue and 16% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.

Latin America holds 8% of the global algal protein market in 2025, worth USD 81.2 million rising to USD 196.65 million in 2034. That makes it the fourth-largest region covered, in 2025 and again in 2034.

Share climbs to 9% by 2034, because it outgrows the market's 8.9%; the revenue added here is disproportionate to where the region started.

Spirulina leads here as it does globally, at 48% of 2025 revenue, and Chlorella again grows fastest at 10.26%. Per-axis and per-country detail for Latin America sits in the full report.

Brazil is the largest market within Latin America, generating USD 40.6 million in 2025 and projected to reach USD 98.3 million by 2034. It accounts for 50% of regional revenue in the base year, the largest single share without dominating the region outright. Regional revenue of USD 81.2 million in 2025 and USD 196.65 million in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Composition here matches the global split: the largest line is Spirulina at 48% of 2025 revenue, easing to 44% by 2034, and the fastest is Chlorella at 10.26%, from 34% to 38%. Since 50% of Latin America's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Brazil carries its own source breakdown in the full report.

Brazil regulates algal protein intended for food use through the National Health Surveillance Agency, known as ANVISA, which classifies novel ingredients and sets the conditions under which they may be marketed. A supplier introducing an algal species not already recognised as a conventional food ingredient must submit a technical dossier demonstrating safety and identity, following ANVISA's framework for new foods and new ingredients, before the product can be sold domestically. Once cleared, the ingredient is subject to ANVISA's labelling rules, which govern nutrition declarations, allergen warnings, and permitted claims regarding protein content or origin. Products positioned as functional foods or supplements face additional requirements under ANVISA's specific categories for those product types, and imported algal protein must also clear sanitary registration before distribution within Brazil.

Brazil does not have a competitive structure of its own; position here is position on the source axis reported above. Spirulina, at 48% of 2025 revenue, is where the volume sits, and Chlorella, growing at 10.26%, is where position changes hands over the forecast period. A supplier weighted toward Latin America is competing over a base of USD 81.2 million in 2025 reaching USD 196.65 million by 2034, 8% of global revenue at the start of that period.

Mexico is sized at USD 24.4 million in 2025, rising to USD 59 million by 2034; 2.4% of global revenue and 30% of Latin America. It is reported separately from Brazil across every segmentation axis in the full report.

USD 60.9 million of 2025 revenue is generated in Middle East and Africa, 6% of the global algal protein market and reaches USD 152.95 million by 2034. Among the five regions it ranks fifth by revenue in both years.

Share climbs to 7% by 2034, so the region grows faster than the market's 8.9% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.

Spirulina leads here as it does globally, at 48% of 2025 revenue, and Chlorella again grows fastest at 10.26%. Revenue for Middle East and Africa is broken out by every segmentation axis and by country in the full report.

USD 23.1 million of Middle East and Africa's 2025 revenue is generated in South Africa, the region's largest market, reaching USD 58.1 million by 2034. Its 38% of base-year regional revenue leads the region, though enough sits elsewhere that Middle East and Africa is not a proxy for it. Regional revenue of USD 60.9 million in 2025 and USD 152.95 million in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Demand in South Africa follows the source mix reported at global level: Spirulina is the largest line at 48% of 2025 revenue, moving to 44% by 2034, while Chlorella grows fastest at 10.26% and takes its share from 34% to 38%. With 38% of Middle East and Africa concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. The full report reports South Africa by source separately.

South Africa regulates food ingredients including algal protein under the Foodstuffs, Cosmetics and Disinfectants Act, administered by the Department of Health, with compositional and labelling requirements set out in the associated food labelling regulations. A supplier must ensure the algal source is recognised as fit for human consumption and that any health or nutrient content claim made on packaging meets the substantiation standards those regulations require. The South African Bureau of Standards maintains voluntary standards that many food manufacturers reference for quality and safety conformity, and compliance with these can support market access even where not strictly mandatory. Imported algal protein ingredients are additionally subject to port health inspection and must carry documentation confirming they meet the same compositional and labelling rules applied to domestically produced food ingredients.

What separates suppliers in South Africa is where they sit on the source axis, not which country they serve. The commercially relevant division is 48% of 2025 revenue in Spirulina, where the volume is, against 10.26% growth in Chlorella, where share moves. A supplier weighted toward Middle East and Africa is competing over a base of USD 60.9 million in 2025, reaching USD 152.95 million by 2034 on the trajectory this study models.

1.8% of global revenue is generated in the United Arab Emirates; USD 18.3 million in 2025, reaching USD 45.9 million in 2034, and 30% of Middle East and Africa.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Source, Product Form, Application, Cultivation Method, Distribution Channel, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.